Sorenson, Corinna, Naci, Huseyin 
ORCID: 0000-0002-7192-5751, Cylus, Jonathan ORCID: 0000-0001-8269-1578 and Mossialos, Elias ORCID: 0000-0001-8664-9297
(2011)
Evidence of comparative efficacy should have a formal role in European drug approvals.
British Medical Journal, 343 (7822).
d4849-d4849.
ISSN 0959-8138
|
PDF
Download (306kB) | Preview |
Identification Number: 10.1136/bmj.d4849
Abstract
Despite methodological concerns, comparative efficacy evidence should be required at the time of drug approval, says Corinna Sorenson and colleagues, to allow patients, clinicians, and other healthcare decision makers to determine whether a new drug is superior, equivalent, or inferior to its existing alternatives.
| Item Type: | Article |
|---|---|
| Official URL: | http://www.bmj.com/ |
| Additional Information: | © 2011 BMJ Publishing Group |
| Divisions: | Social Policy LSE Health Lifecourse, Ageing & Population Health |
| Subjects: | R Medicine > RA Public aspects of medicine R Medicine > RM Therapeutics. Pharmacology |
| Date Deposited: | 09 Sep 2011 12:50 |
| Last Modified: | 13 Nov 2024 06:27 |
| URI: | http://eprints.lse.ac.uk/id/eprint/38191 |
Actions (login required)
 |
View Item |
Download Statistics
Download Statistics